Compare Stocks: CLDX, EXEL, BMRN, and ARWR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.59 -1.9%	$81.10	$18.14 ▼ $95.49	$12.29B	1.27	2.03 million shs	1.10 million shs
BMRN BioMarin Pharmaceutical	$68.53 -2.4%	$59.35	$49.26 ▼ $70.98	$13.60B	0.24	2.25 million shs	2.31 million shs
CLDX Celldex Therapeutics	$42.61 -5.0%	$36.31	$20.37 ▼ $45.14	$3.52B	0.87	1.02 million shs	670,859 shs
EXEL Exelixis	$50.61 +0.5%	$54.21	$33.76 ▼ $57.57	$12.48B	0.44	2.73 million shs	1.95 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-1.90%	-0.28%	+19.02%	+11.63%	+328.16%
BMRN BioMarin Pharmaceutical	-2.43%	+11.50%	+16.87%	+32.27%	+17.55%
CLDX Celldex Therapeutics	-5.04%	+2.53%	+11.63%	+35.96%	+70.51%
EXEL Exelixis	+0.46%	-3.05%	-9.25%	+0.96%	+31.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.59 -1.9%	$81.10	$18.14 ▼ $95.49	$12.29B	1.27	2.03 million shs	1.10 million shs
BMRN BioMarin Pharmaceutical	$68.53 -2.4%	$59.35	$49.26 ▼ $70.98	$13.60B	0.24	2.25 million shs	2.31 million shs
CLDX Celldex Therapeutics	$42.61 -5.0%	$36.31	$20.37 ▼ $45.14	$3.52B	0.87	1.02 million shs	670,859 shs
EXEL Exelixis	$50.61 +0.5%	$54.21	$33.76 ▼ $57.57	$12.48B	0.44	2.73 million shs	1.95 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-1.90%	-0.28%	+19.02%	+11.63%	+328.16%
BMRN BioMarin Pharmaceutical	-2.43%	+11.50%	+16.87%	+32.27%	+17.55%
CLDX Celldex Therapeutics	-5.04%	+2.53%	+11.63%	+35.96%	+70.51%
EXEL Exelixis	+0.46%	-3.05%	-9.25%	+0.96%	+31.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$97.33	13.72% Upside
BMRN BioMarin Pharmaceutical	2.70	Moderate Buy	$88.00	28.41% Upside
CLDX Celldex Therapeutics	2.86	Moderate Buy	$55.46	30.16% Upside
EXEL Exelixis	2.32	Hold	$49.79	-1.63% Downside

Current Analyst Ratings Breakdown

Latest CLDX, EXEL, BMRN, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/11/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B) ➝ Buy (A-)
8/10/2026	BMRN BioMarin Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$111.00 ➝ $114.00
8/7/2026	BMRN BioMarin Pharmaceutical	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$95.00 ➝ $97.00
8/7/2026	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$119.00 ➝ $124.00
8/7/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$50.00 ➝ $60.00
8/7/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$40.00 ➝ $46.00
8/7/2026	CLDX Celldex Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $53.00
8/6/2026	EXEL Exelixis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$56.00 ➝ $52.00
8/6/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$115.00 ➝ $120.00
8/6/2026	EXEL Exelixis	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$52.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$829.45M	14.54	$0.12 per share	730.73	$3.31 per share	25.86
BMRN BioMarin Pharmaceutical	$3.22B	4.12	$2.78 per share	24.62	$32.66 per share	2.10
CLDX Celldex Therapeutics	$1.54M	2,172.83	N/A	N/A	$9.10 per share	4.68
EXEL Exelixis	$2.32B	5.40	$3.04 per share	16.64	$7.44 per share	6.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	185.22	12.17	0.49	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	N/A
EXEL Exelixis	$782.57M	$3.18	15.92	13.60	1.50	35.33%	42.17%	31.76%	N/A

Latest CLDX, EXEL, BMRN, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
CLDX Celldex Therapeutics	N/A	11.82	11.82
EXEL Exelixis	N/A	3.46	3.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BMRN BioMarin Pharmaceutical	98.71%
CLDX Celldex Therapeutics	N/A
EXEL Exelixis	85.27%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
BMRN BioMarin Pharmaceutical	0.68%
CLDX Celldex Therapeutics	5.20%
EXEL Exelixis	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable

CLDX, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL)

August 13 at 10:13 AM | globenewswire.com

Bank of America Securities Reaffirms Their Sell Rating on Exelixis (EXEL)

August 13 at 8:45 AM | theglobeandmail.com

Mary Beckerle Sells 9,812 Shares of Exelixis (NASDAQ:EXEL) Stock

August 13 at 7:06 AM | insidertrades.com

Annex Advisory Services LLC Makes New Investment in Exelixis, Inc. $EXEL

August 13 at 3:14 AM | marketbeat.com

Exelixis (EXEL) Q2 2026 Earnings Call Transcript

August 12 at 12:13 AM | finance.yahoo.com

Insider Selling: Exelixis (NASDAQ:EXEL) Director Sells $526,511.92 in Stock

August 12 at 9:07 PM | marketbeat.com

EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)

August 12 at 10:21 AM | businesswire.com

Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)

August 10, 2026 | prnewswire.com

Bank of America Corp DE Sells 578,181 Shares of Exelixis, Inc. $EXEL

August 10, 2026 | marketbeat.com

Exelixis, Inc. $EXEL Shares Acquired by Assenagon Asset Management S.A.

August 10, 2026 | marketbeat.com

Why this top-ranked IBD 50 stock just tumbled on its earnings

August 8, 2026 | msn.com

Amundi Sells 121,348 Shares of Exelixis, Inc. $EXEL

August 8, 2026 | marketbeat.com

Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by Analysts

August 8, 2026 | americanbankingnews.com

Exelixis (NASDAQ:EXEL) Rating Lowered to "Buy" at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Exelixis (NASDAQ:EXEL) Lowered to "Buy" Rating by Wall Street Zen

August 8, 2026 | marketbeat.com

What is Zacks Research's Estimate for Exelixis Q3 Earnings?

August 8, 2026 | americanbankingnews.com

Exelixis Earnings Call: Cabo Strength, Zanza Awaited

August 7, 2026 | tipranks.com

Quantinno Capital Management LP Boosts Holdings in Exelixis, Inc. $EXEL

August 7, 2026 | marketbeat.com

Exelixis (NASDAQ:EXEL) Downgraded by Leerink Partners to "Market Perform"

August 7, 2026 | americanbankingnews.com

Exelixis (NASDAQ:EXEL) Price Target Raised to $51.00 at Stifel Nicolaus

August 7, 2026 | americanbankingnews.com

What is Zacks Research's Estimate for Exelixis Q4 Earnings?

August 7, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$85.59 -1.66 (-1.90%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$85.90 +0.30 (+0.36%)

As of 07:41 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BioMarin Pharmaceutical NASDAQ:BMRN

$68.53 -1.71 (-2.43%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$68.53 0.00 (-0.01%)

As of 07:48 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Celldex Therapeutics NASDAQ:CLDX

$42.61 -2.26 (-5.04%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$42.36 -0.24 (-0.57%)

As of 07:40 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Exelixis NASDAQ:EXEL

$50.61 +0.23 (+0.46%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$50.94 +0.33 (+0.66%)

As of 07:41 AM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLDX, EXEL, BMRN, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLDX, EXEL, BMRN, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLDX, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Celldex Therapeutics NASDAQ:CLDX

Exelixis NASDAQ:EXEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLDX, EXEL, BMRN, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLDX, EXEL, BMRN, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLDX, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Celldex Therapeutics NASDAQ:CLDX

Exelixis NASDAQ:EXEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools